Professional
Added to YB: 2025-03-27
Pitch date: 2025-03-22
HROW [bullish]
Harrow, Inc.
+21.39%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$28.94
Price Target
57.00 (+62%)
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Show full summary:
H.C. Wainwright Bullish on Harrow Health (HROW), $57 Target
HROW: Buy rating, $57 PT. Q4/FY24 results beat expectations. 2025 outlook: 40%+ revenue growth. VEVYE Access program to boost adoption. Leading dry eye treatment potential. Valuation supported by comps. Risks: market uptake, debt servicing.
Read full article (1 min)